Key Insights

Highlights

Success Rate

40% trial completion

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 62/100

Termination Rate

12.5%

3 terminated out of 24 trials

Success Rate

40.0%

-46.5% vs benchmark

Late-Stage Pipeline

13%

3 trials in Phase 3/4

Results Transparency

50%

1 of 2 completed with results

Key Signals

1 with results40% success

Data Visualizations

Phase Distribution

18Total
Not Applicable (3)
Early P 1 (5)
P 1 (1)
P 2 (6)
P 3 (3)

Trial Status

Recruiting13
Terminated3
Active Not Recruiting3
Completed2
Unknown1
Withdrawn1

Trial Success Rate

40.0%

Benchmark: 86.5%

Based on 2 completed trials

Clinical Trials (24)

Showing 20 of 20 trials
NCT05565521Phase 2Active Not RecruitingPrimary

UNITy-BasED MR-Linac Adaptive Simultaneous Integrated Hypofractionated Boost Trial for High Grade Glioma in the Elderly

NCT07100730Phase 3Recruiting

Study of TLX101-Tx Plus Standard of Care (SoC) Versus SoC Alone for the Treatment of Patients With Recurrent Glioblastoma

NCT04762069Phase 2Active Not RecruitingPrimary

A Study of Berubicin in Adult Subjects With Recurrent Glioblastoma Multiforme

NCT06496971Phase 3Recruiting

A Prospective Pivotal Study to Evaluate the Efficacy and Safety of Avastin® Bevacizumab (BEV) With or Without Microbubble-mediated Focused Ultrasound (FUS-MB) Using NaviFUS System in Recurrent Glioblastoma Multiforme Patients

NCT05653622Phase 2RecruitingPrimary

Simultaneous Integrated Boost FDOPA Positron Emission Tomography (PET) Guided in Patients With Partially- or Non-operated Glioblastoma

NCT04825275Early Phase 1Terminated

Neuro-pharmacological Properties of Repurposed Posaconazole in Glioblastoma: A Phase 0 Clinical Trial

NCT04869449Early Phase 1Terminated

Neuro-pharmacological Properties of Repurposed Ketoconazole in Glioblastomas

NCT06991101Phase 2Recruiting

Ruxolitinib With Radiation and Temozolomide Compared to Radiation and Temozolomide for Newly Diagnosed Glioblastoma

NCT05052957Phase 2Recruiting

hSTAR GBM (Hematopoetic Stem Cell (HPC) Rescue for GBM)

NCT06954636RecruitingPrimary

Prognostic Potential of Olfactory Function in Glioblastoma: a Prospective Observational Study

NCT05720078Not ApplicableRecruitingPrimary

UNIty-Based MR-Linac Guided Adaptive RadioThErapy for High GraDe Glioma-3 (UNITED-3)

NCT06781372Not ApplicableNot Yet Recruiting

Patient's Derived Organoids for Drug Screening in Glioblastoma

NCT04469699Phase 2TerminatedPrimary

Stereotactical Photodynamic Therapy With 5-aminolevulinic Acid (Gliolan®) in Recurrent Glioblastoma

NCT04614909Early Phase 1Active Not Recruiting

Study of Pamiparib in Newly Diagnosed and rGBM

NCT05271240Phase 3Recruiting

Repeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozolomide and Radiation Compared to Temozolomide and Radiation Alone in Newly Diagnosed GBM

NCT05954858Not ApplicableRecruiting

Surgical Tissue Flap to Bypass the Blood Brain Barrier in Glioblastoma

NCT05977738Early Phase 1CompletedPrimary

Repurposed Drugs in Research for Cancer Clinical Trials- Pitavastatin

NCT06283927Recruiting

The RECSUR-study: Resection Versus Best Oncological Treatment for Recurrent Glioblastoma (ENCRAM 2302)

NCT06118723Recruiting

The SUPRAMAX Study: Supramaximal Resection Versus Maximal Resection for High-Grade Glioma Patients (ENCRAM 2201)

NCT06146738Recruiting

The PALSUR-study: Palliative Care Versus Surgery in High-grade Glioma Patients (ENCRAM 2203)

Scroll to load more

Research Network

Activity Timeline